Canadian Gold Corp: 1 director

A director at Canadian Gold Corp sold 185,560 shares at 0.235CAD and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of b...

Delivra Health Brands Inc. (TSXV: DHB / OTCQB: DHBUF) A Health & Wellness Company Endorsed by Major Retail/Pharmacy Chains – Initiating Coverage

Fundamental Research Corp has issued a report entitled “A Health & Wellness Company Endorsed by Major Retail/Pharmacy Chains – Initiating Coverage” and dated September 12, 2023. The full report is now at

Due to a more favourable environment, CANOPY GROWTH slightly increases to Slightly Negative

CANOPY GROWTH (CA), a company active in the Pharmaceuticals industry, slightly increases its general evaluation. The independent financial analyst theScreener just confirmed the stock market behaviour of the title as risky. At the fundamental level, theScreener confirms the rating of 0 out of 4 stars; given the more favourable environment, the title's overall rating is upgraded to Slightly Negative even if it remains under pressure. As of the analysis date March 18, 2022, the closing price was CAD 8.97 and its target price was estimated at CAD 6.40.

Kempower: new CEO appointed

This morning, Kempower announced it has appointed Bhasker Kaushal as its new President and CEO as of 2nd June 2025. This follows Tomi Ristimäki's decision to step down. A transition period with Tomi Ristimäki supporting Bhasker Kaushal will last until December 2025.

Daily Healthcare - May 6th, 2025

Hugo Boss: reassuring Q1 numbers and FY25 outlook reiterated

Hugo Boss has reported reassuring Q1 2025 results this morning: the FX-n sales decline of 2% was less negative than expected (CSSe: -4%) while the EBIT contraction was also less pronounced than initially feared (-12% to EUR61m vs. CSSe EUR50m) as another GM miss was offset by tight opex discipline.